Multivirus-specific Cytotoxic T Lymphocytes (mCTL)
Treatment of EBV, CMV, and Adenovirus Infections in Primary Immunodeficiency Disorders With Viral-specific Cytotoxic T-Lymphocytes
PIDD represent an expanding group of genetic disorders that compromise immunity against bacteria, viruses, and fungi. The most severe forms of PIDD cause profound susceptibility to opportunistic infections due to impaired or absent T-cell immunity. These diseases can be rapidly fatal unless treated via hematopoietic stem cell transplantation (HSCT). Chronic viral illnesses are a common presenting feature of many of these disorders, and studies have shown that survival of HSCT is profoundly impacted by the patient's pre-transplant disease status. Primary infections with viruses such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are common, and respiratory viruses such as adenovirus also frequently cause infection. In patients with severe combined immunodeficiency (SCID), a prior study identified these viruses as the most common causes of mortality in the immediate period following HSCT. Though some forms of PIDD are amenable to HSCT without requiring conditioning chemotherapy, many forms require a variable degree of pre-conditioning to ensure that stable engraftment of the donor cells is achieved. The administration of cytotoxic chemotherapy used in the conditioning regimens can however increase the risk for regimen related toxicity and for some patients (especially those with active viral infections) this risk is particularly high, leading to high treatment related mortality rates. For these reasons, many such patients are not even considered candidates for HSCT or are delayed getting to HSCT and ultimately succumb to infection before they can receive the transplant.
The primary objective of this study is to determine the safety of administering third-party multivirus-specific cytotoxic T lymphocytes (mCTL) from adult CMV seropositive donors to treat refractory viral infections in patients with primary immunodeficiency disorders (PIDD) prior to hematopoietic stem cell transplantation (HSCT).
Visão geral do estudo
Descrição detalhada
Since recovery of virus-specific T cells is clearly associated with protection from infection with each of these viruses, adoptive immunotherapy to decrease the time to immune reconstitution is an attractive approach. Virus-specific T cells generated by repeated stimulation with antigen presenting cells (APCs) expressing viral antigens have been evaluated in clinical trials to prevent and treat viral infections in immunocompromised hosts. This approach eliminates alloreactive T cells.
To broaden the specificity of single CTL lines to include the three most common viral pathogens of stem cell recipients, investigators reactivated CMV and adenovirus-specific T cells by using mononuclear cells transduced with a recombinant adenoviral vector encoding the CMV antigen pp65 (Ad5f35CMVpp65). Subsequent stimulations with EBV-LCL transduced with the same vector both reactivated EBV-specific T cells and maintained the expansion of the activated adenovirus and CMV-specific T cells. This method reliably produced CTLs with cytotoxic function specific for all three viruses, which investigators infused into 14 stem cell recipients in a Phase I prophylaxis study. They observed recovery of immunity to CMV and EBV in all patients but an increase in adenovirus-specific T cells was only seen in patients who had evidence of adenovirus infection pre-infusion. A follow-up study in which the frequency of adenovirus-specific T cells was increased in the infused CTLs produced similar results, thus highlighting the importance of endogenous antigen to promote the expansion of infused T cells in vivo. Nevertheless, all patients in both clinical trials with pre-infusion CMV, adenovirus or EBV infection or reactivation were able to clear the infection, including one patient with severe adenoviral pneumonia requiring ventilatory support. CTLs recognizing multiple antigens can therefore produce clinically relevant effects against all three viruses.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20010
- Childrens National Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diagnosis of primary immunodeficiency with established plan to undergo myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant for treatment thereof or diagnosis of a form of primary immunodeficiency for which hematopoietic stem cell transplantation is not indicated.
- Active infection with EBV, CMV, and/or Adenovirus, unable to be successfully controlled with standard therapy.
- Steroids less than 0.5 mg/kg/day prednisone
- Karnofsky/Lansky score of ≥ 50
- ANC greater than 500/µL.
- Bilirubin <2x, AST <3x, Serum creatinine <2x upper limit of normal, Hgb >8.0
- Pulse oximetry of > 90% on room air
- Negative pregnancy test (if female of childbearing potential)
- Patient or parent/guardian capable of providing informed consent.
Exclusion Criteria:
- Patients with other uncontrolled infections (see 2.3.2 for definitions)
- Patients who received ATG, Campath, or other T cell immunosuppressive monoclonal antibodies in the last 28 days
- Received donor lymphocyte infusion in last 28 days
- Diagnosis of Omenn's syndrome or MHC class I deficiency
- Active and uncontrolled malignancy
- Pregnant or lactating
- Unable to wean steroids to ≤0.5 mg/kg/day prednisone.
- Patients with Grade 3 hyperbilirubinemia
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: mCTLs against three viruss
The investigator will use 3 different dose levels starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2.
They will give the option of administering 2 additional doses (at the same level) of the same or different cell lines, 28 days after the first dose, in subjects that have limited or no improvement in viral count after one dose in the absence of any toxicities attributable to the infusion,or who receive other therapy that may affect the persistence or function of the infused mCTLs.
|
The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment.
This trial will be performed as dose-escalation study.
Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors.
These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Assessments of patients with adverse events after mCTLs infusion
Prazo: 45 days
|
The safety endpoint will be defined as acute GvHD grades III-IV related to the T cell product within 45 days of the last VST dose and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE)
|
45 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Assessments of viral load response to the mCTLs infusion
Prazo: 12 months
|
Increase in viral load of at least 50% from baseline or dissemination to other sites of disease.
|
12 months
|
|
Avaliações de Imunidade Antiviral
Prazo: 12 meses
|
O soro do paciente e as células mononucleares do sangue periférico serão monitorados quanto à atividade específica do vírus por estudos fenotípicos e funcionais, incluindo ELIspot com misturas apropriadas de peptídeos específicos virais e peptídeos epítopos restritos a HLA disponíveis, coloração intracelular de citocinas, perfil de citocinas séricas e/ou outros ensaios à medida que tornar-se disponível para fins de perfis imunológicos.
|
12 meses
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Catherine Bollard, MD, Children's National Research Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TREPID
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Refractory Viral Infections
-
University of Wisconsin, MadisonConcluídoInfecção viral respiratóriaEstados Unidos
-
Sinovac Biotech Co., LtdRetiradoInfecção, Viral, EnterovírusChina
-
Sinovac Biotech Co., LtdConcluídoInfecção, Viral, EnterovírusChina
-
Hospices Civils de LyonRecrutamento
-
National Institute of Allergy and Infectious Diseases...ConcluídoInfecção Viral do Nilo OcidentalEstados Unidos
-
ShireConcluído
-
Materia Medica HoldingConcluídoEstudo Clínico da Eficácia e Segurança da Rafamina no Tratamento da ARVI em Crianças de 12 a 18 AnosInfecção viral respiratória agudaFederação Russa
-
Children's Hospital Medical Center, CincinnatiHoxworth Blood CenterRecrutamentoTransplante Alogênico de Células Tronco | Infecção viral | Reativação viralEstados Unidos
-
University Health Network, TorontoRescindidoInfecção viral da hepatite CCanadá
-
Nanjing Zenshine PharmaceuticalsAinda não está recrutando